Selexipag
- Generic Name
- Selexipag
- Brand Names
- Uptravi, Uptravi Titration Pack
- Drug Type
- Small Molecule
- Chemical Formula
- C26H32N4O4S
- CAS Number
- 475086-01-2
- Unique Ingredient Identifier
- 5EXC0E384L
- Background
Selexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization. PAH is a relatively rare disease with usually a poor prognosis requiring more treatment options to prolong long-term outcomes. Marketed by Actelion Pharmaceuticals und...
- Indication
Selexipag is indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization.
- Associated Conditions
- Pulmonary arterial hypertension WHO functional class I
- Associated Therapies
- -
Potential Pharmacokinetic Interaction Between Selexipag and Midazolam in Healthy Male Subjects
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2016-10-13
- Lead Sponsor
- Actelion
- Target Recruit Count
- 20
- Registration Number
- NCT02791815
- Locations
- 🇫🇷
Investigator Site, Gieres, France
A Clinical Study to Investigate the Effect of Gemfibrozil or Rifampicin on Blood Concentrations of Selexipag in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-05-12
- Last Posted Date
- 2016-07-21
- Lead Sponsor
- Actelion
- Target Recruit Count
- 40
- Registration Number
- NCT02770222
- Locations
- 🇩🇪
Investigator Site, Kiel, Germany
The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
- Conditions
- Interventions
- First Posted Date
- 2015-09-23
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Actelion
- Target Recruit Count
- 247
- Registration Number
- NCT02558231
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Boston University Medical Center, Boston, Massachusetts, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Actelion
- Target Recruit Count
- 34
- Registration Number
- NCT02471183
- Locations
- 🇺🇸
University of Michigan Health System, Ann Arbor, Michigan, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Duke Unversity, Durham, North Carolina, United States
Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2016-05-10
- Lead Sponsor
- Actelion
- Target Recruit Count
- 74
- Registration Number
- NCT02260557
- Locations
- 🇬🇧
Investigator Site, Salford, United Kingdom
Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-08-01
- Last Posted Date
- 2014-08-01
- Lead Sponsor
- Actelion
- Target Recruit Count
- 159
- Registration Number
- NCT02206204
- Locations
- 🇺🇸
Covance Clinical Research Unit, Evansville, Indiana, United States
Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg
- First Posted Date
- 2014-08-01
- Last Posted Date
- 2014-08-01
- Lead Sponsor
- Actelion
- Target Recruit Count
- 80
- Registration Number
- NCT02206295
- Locations
- 🇳🇱
QPS, Groningen, Netherlands
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
- First Posted Date
- 2010-04-19
- Last Posted Date
- 2018-01-11
- Lead Sponsor
- Actelion
- Target Recruit Count
- 1156
- Registration Number
- NCT01106014
- Locations
- 🇺🇸
The Ohio State University Medical Center, Columbus, Ohio, United States
🇵🇱"Instytut Gruźlicy i Chorób Płuc Klinika Chorób Wewnętrznych Klatki Piersiowej", Warszawa, Poland
🇵🇱"Instytut Kardiologii Collegium Medium UJ Krakowski Szpital Specjalistyczny im Jana Pawła II Klinika Chorób Serca i Naczyń", Krakow, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.